A Proteome-wide, Multi-Omics Analysis Implicates Novel Protein Dysregulation in Post-Traumatic Stress Disorder
Jiawei Wang,Hongyu Li,Rashaun Wilson,Weiwei Wang,TuKiet Lam,Traumatic Stress Brain Research Group,David A Lewis,Jill Glausier,Paul E Holtzheimer,Matthew Friedman,Kenneth Williams,Marina R Picciotto,Angus C Nairn,John H Krystal,Ronald S Duman,Hongyu Zhao,Matthew J Girgenti
DOI: https://doi.org/10.1101/2023.05.05.23289589
2023-01-01
Abstract:Post-traumatic stress disorder (PTSD) is a common and disabling psychiatric disorder. Here we present findings from the first proteome-wide study of the postmortem PTSD brain. We performed tandem mass spectrometry on large cohort of donors (N = 66) in two prefrontal cortical areas and found differentially expressed proteins and co-expression modules disturbed in PTSD. Integrative analysis pointed to hsa-mir-589 as a regulatory miRNA responsible for disruptions in neuronal protein networks for PTSD, including the GABA vesicular transporter, SLC32A1. In addition, we identified significant enrichment of risk genes for Alzheimers Disease (N= 94,403), major depression (N = 807,553), and schizophrenia (N = 35,802) within PTSD co-expression protein modules, suggesting shared molecular pathology. Our findings highlight the altered proteomic landscape of postmortem PTSD brain and provide a novel framework for future studies integrating proteomic profiling with transcriptomics in postmortem human brain tissue.
### Competing Interest Statement
JHK Financial Disclosure: Consultant (Note: The Individual Consultant Agreements listed below are less than $5000 per year): Aptinyx, Inc.; Atai Life Sciences; AstraZeneca Pharmaceuticals; Biogen, Idec,; MA; Biomedisyn Corporation; Bionomics, Limited (Australia); Boehringer Ingelheim International; Cadent Therapeutics, Inc.; Clexio Bioscience, Ltd.; COMPASS Pathways, Limited, UK; Concert Pharmaceuticals, Inc.; Epiodyne, Inc.; EpiVario, Inc.; Greenwich Biosciences, Inc.; Heptares Therapeutics, Limited (UK); Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Perception Neuroscience Holdings, Inc.; Spring Care, Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Industries; Taisho Pharmaceutical Co., Ltd. Board of Directors: Freedom Biosciences, Inc. Scientific Advisory Board: Biohaven Pharmaceuticals; BioXcel Therapeutics, Inc. (Clinical Advisory Board); Cadent Therapeutics, Inc. (Clinical Advisory Board); Cerevel; Therapeutics, LLC; EpiVario, Inc.; Eisai, Inc.; Jazz Pharmaceuticals, Inc.; Lohocla Research Corporation; Novartis Pharmaceuticals Corporation; PsychoGenics, Inc.; RBNC Therapeutics, Inc.; Tempero Bio, Inc.; Terran Biosciences, Inc. Stock: Biohaven Pharmaceuticals; Sage Pharmaceuticals; Spring Care, Inc. Stock Options: Biohaven Pharmaceuticals Medical Sciences; EpiVario, Inc.; RBNC Therapeutics, Inc.; Terran Biosciences, Inc.; Tempero Bio, Inc. Income Greater than $10 000. Editorial Board: EditorBiological Psychiatry. Patents and Inventions: 1. Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948. 5 September 1995; 2. Vladimir, Coric, Krystal, John H, Sanacora, GerardGlutamate Modulating Agents in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: 15 July 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017; 3. Charney D, Krystal JH, Manji H, Matthew S, Zarate C.Intranasal Administration of Ketamine to Treat Depression United States Patent Number: 9592207, Issue date: 3/14/2017. Licensed to Janssen Research & Development; 4. Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University Methods for Treating Suicidal Ideation, Patent Application No. 15/379,013 filed on 14 December 2016 by Yale University Office of Cooperative Research; 5. Arias A, Petrakis I, Krystal JH.Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. 2 April 2014. Filed by Yale University Office of Cooperative Research.; 6. Chekroud, A., Gueorguieva, R., & Krystal, JH. Treatment Selection for Major Depressive Disorder [filing date 3 June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University; 7. Gihyun, Yoon, Petrakis I, Krystal JHCompounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on 10 January 2017 by Yale University Office of Cooperative Research OCR 7088 US01; 8. Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. US Provisional Patent Application No. 62/719,935 filed on 20 August 2018 by Yale University Office of Cooperative Research OCR 7451 US01; 9. John Krystal, Godfrey Pearlson, Stephanie O'Malley, Marc Potenza, Fabrizio Gasparini, Baltazar Gomez- Mancilla, Vincent Malaterre. Mavoglurant in treating gambling and gaming disorders. US Provisional Patent Application No. 63/125,181filed on 14 December 2020 by Yale University Office of Cooperative Research OCR 8065 US00; NON Federal Research Support: AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant Center for Translational Neuroscience of Alcoholism [CTNA-4]; Novartis provides the drug, Mavoglurant, for research related to NIAAA grant Center for Translational Neuroscience of Alcoholism [CTNA-4]; Cerevel provides the drug PF-06412562 for A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia (1 U01 MH121766-01).
### Funding Statement
The research reported here was supported by the Department of Veterans Affairs, Veteran Health Administration, VISN1 Career Development Award, a Brain and Behavior Research Foundation Young Investigator Award, and an American Foundation for Suicide Prevention Young Investigator Award to M.J.G. The proteomics was supported in part by the Yale/NIDA Neuroproteomics Centre (NIH DA018343) to M.J.G.
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Yale School of Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
All data produced in the present study are available upon reasonable request to the authors